8-K
false 0000200406 0000200406 2020-10-01 2020-10-01 0000200406 us-gaap:CommonStockMember 2020-10-01 2020-10-01 0000200406 jnj:A0.250NotesDue2022Member 2020-10-01 2020-10-01 0000200406 jnj:M0.650NotesDueMay20242Member 2020-10-01 2020-10-01 0000200406 jnj:M5.50NotesDueNovember20241Member 2020-10-01 2020-10-01 0000200406 jnj:A1.150NotesDue2028Member 2020-10-01 2020-10-01 0000200406 jnj:A1.650NotesDue2035Member 2020-10-01 2020-10-01

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of report (Date of earliest event reported): October 1, 2020

 

 

Johnson & Johnson

(Exact name of registrant as specified in its charter)

 

 

 

New Jersey   1-3215   22-1024240

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code:

732-524-0400

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, Par Value $1.00   JNJ   New York Stock Exchange
0.250% Notes Due January 2022   JNJ22   New York Stock Exchange
0.650% Notes Due May 2024   JNJ24   New York Stock Exchange
5.50% Notes Due November 2024   JNJ24BP   New York Stock Exchange
1.150% Notes Due November 2028   JNJ28   New York Stock Exchange
1.650% Notes Due May 2035   JNJ35   New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


Item 8.01  Other Events

On October 1, 2020, Johnson & Johnson, a New Jersey corporation (“Johnson & Johnson”) announced that it has completed the acquisition of Momenta Pharmaceuticals, Inc., a Delaware corporation, a company that discovers and develops novel therapies for immune-mediated diseases, in an all-cash transaction for approximately $6.5 billion.

A copy of the press release issued by Johnson & Johnson on October 1, 2020 announcing the acquisition filed as Exhibit (a)(5)(E) to the Schedule TO-T/A filed by Johnson & Johnson with the U.S. Securities and Exchange Commission (the “SEC”) on October 1, 2020 is incorporated herein by reference as Exhibit 99.1.

Item 9.01  Exhibits

(d) Exhibits.

 

  Exhibit  
No.
  

Description of Exhibit

99.1    Press Release, dated October 1, 2020, incorporated herein by reference to Exhibit (a)(5)(E) of the Schedule TO-T/A filed by Johnson & Johnson with the SEC on October 1, 2020.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Johnson & Johnson
    (Registrant)

Date: October 1, 2020

    By:  

/s/ Renee A. Brutus

      Renee A. Brutus
      Assistant Secretary